Contact Us
Drug Search Results
More Filters [+]

Nifedipine

Alternative Names: nifedipine, adalat, coracten, adalat la, adalat cr, adalat gits, adalat xl, baya1040, bay1040, bay a1040, afeditab cr, nifedipin, procardia xl, procardia
Latest Update: 2024-12-17
Latest Update Note: Clinical Trial Update

Product Description

Nifedipine is a calcium channel blocker in the dihydropyridine subclass. It is primarily used as an antihypertensive and as an anti-anginal medication. FDA-approved indications include chronic stable angina, hypertension (Sourced from: https://pubmed.ncbi.nlm.nih.gov/30725737/)

Mechanisms of Action: Calcium Channel Blocker

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Nifedipine

Countries in Clinic: China, France, India, Unknown Location

Active Clinical Trial Count: 5

Highest Development Phases

Phase 3: Fetal Membranes, Premature Rupture|Obstetric Labor, Premature

Phase 1: Angina Pectoris|Angina, Stable|Coronary Disease|Hypertension|Hypertension, Renal

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
TOCOPROM

P3

Recruiting

Obstetric Labor, Premature|Fetal Membranes, Premature Rupture

2025-11-01

CTR20212749

P1

Not yet recruiting

Hypertension, Renal|Angina Pectoris

None

CTR20191815

P1

Not yet recruiting

Hypertension

None

CTR20182008

P1

Active, not recruiting

Coronary Disease|Angina, Stable|Hypertension

None

Recent News Events

Date

Type

Title

09/29/2023

News Article

 Battery Market Size, Key Drivers, Industry Developments, Share, Future Growth Prospects And Forecast To 2030

09/15/2023

News Article

 Selective Laser Sintering Equipment Market Share, Size, Growth Drivers & Opportunities Forecast, 2030

09/13/2023

News Article

 Nifedipine Market Size is growing at a CAGR of 12.3% forecast till 2030 and this is report is thorough and in-depth examination of the market.

09/13/2023

News Article

 Competitive Intelligence Tools Software Market Size, Share and Growth Report 2023-2030

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions